全球流感疫苗市场：趋势、预测、竞争分析（~2030 年）

预计2030年，全球流感疫苗市场规模将达112亿美元，2024年至2030年复合年增长率为6.8%。该市场的主要驱动因素包括对更有效、侵入性更小的流感疫苗的需求不断增加、人们对流感疫苗益处的认识不断提高以及政府促进流感疫苗接种的支持措施。全球流感疫苗市场前景广阔，医院、零售药局、政府供应管道都有机会。

• 由于其安全性和有效性，灭活疫苗的需求正在增加，预计在预测期内将出现高速成长。
• 在这个市场中，医院和零售药局预计将在预测期内实现最高成长，因为它们是获得流感疫苗最容易、最容易获得的地点。
• 由于流感流行率高、医疗保健系统完善以及对疫苗接种的偏好，预计北美在预测期内将经历最高的增长。

流感疫苗市场新趋势

流感疫苗市场的新趋势反映了疫苗技术的创新、扩大可及性和不断发展的公共卫生策略。这些趋势正在塑造全球流感预防和治疗的未来。

• 四价疫苗和高剂量疫苗的开发：四价疫苗和高剂量疫苗的趋势引人注目。四价疫苗涵盖四种流感病毒株并提供更广泛的保护。高剂量疫苗专为老年人设计，以改善他们的免疫反应。这些进展旨在提高有效性并提供更好的流感保护。
• 专注于疫苗创新和个人化疫苗：疫苗技术的创新，例如针对个人基因特征量身定制的个人化疫苗，正在获得动力。此类创新可实现更有效、更有针对性的流感预防，提高疫苗接种率并改善整体公共卫生结果。
• 重视每年接种疫苗：为了因应流感病毒株的季节性波动，每年接种疫苗变得越来越重要。每年的疫苗宣传活动已广泛开展，目的是提高疫苗接种覆盖率并降低流感的年发病率。
• 将疫苗接种计划扩大到服务欠缺地区：将疫苗接种计划扩大到服务欠缺地区和农村地区是一个重要趋势。目前正在努力改善低收入和偏远地区的疫苗接种机会，以确保更广泛的覆盖范围并缩小流感预防的差距。
• 与数位健康解决方案整合：与电子健康记录和行动医疗应用程式等数位健康解决方案整合正在改善疫苗追踪和管理。数位工具可以帮助简化疫苗接种流程、加强公共卫生沟通并提高疫苗遵从率。

新兴市场包括四价和高剂量疫苗的开发、注重疫苗创新、强调每年接种疫苗、扩展到服务不足的地区以及与数位健康解决方案的整合等趋势正在重塑流感疫苗市场。这些趋势将加强疫苗的功效、可及性和整体公共卫生策略。

流感疫苗市场近期趋势

流感疫苗市场的最新趋势以技术进步、监管更新和公共卫生策略改进为标誌。这些发展正在改变疫苗的有效性和可用性。

• 四价疫苗的推出：四价疫苗的推出是一项重要的发展，因为与三价疫苗相比，它多了一种株。这些疫苗提供更广泛的保护，正在成为流感预防的标准，提高整体功效并减少季节性流感发病率。
• 高剂量和佐剂疫苗的进展：高剂量和佐剂疫苗是专门为增强老年人的免疫反应而开发的。这些疫苗旨在解决与老龄化相关的免疫力下降问题，提供更好的保护，并降低与流感相关的严重併发症的风险。
• 扩大疫苗取得计画：透过政府补贴和公共卫生计画扩大疫苗取得的努力正在加大。这些计划旨在使疫苗更便宜、更容易获得，特别是对于服务不足的人群和农村地区，并提高疫苗接种率和公共卫生结果。
• 新疫苗配方的出现：正在推出新的疫苗配方，包括具有改进的多系统保护的疫苗配方。这些配方提高了我们应对不断变化的流感病毒的能力，提高了疫苗功效，并有助于更好地管理季节性流感。
• 疫苗分配的全球合作：政府、製药公司和卫生组织之间的全球合作改善了疫苗分配。这些伙伴关係透过扩大疫苗对不同族群（包括低收入和中等收入国家）的覆盖范围，加强了全球流感预防工作。

四价疫苗的引入、高剂量和佐剂疫苗的进步、扩大准入计划、新配方的出现以及全球合作等近期趋势正在对流感疫苗市场产生重大影响。这些进步正在提高疫苗的功效、可及性和整体公共卫生结果。

流感疫苗市场的策略性成长机会

疫苗技术的进步、全球疫苗接种工作的不断增加以及不断变化的公共卫生需求推动了流感疫苗市场的策略性成长机会。这些机会代表了市场扩张和改善健康结果的潜力。

• 扩展到新兴市场：将流感疫苗接种计划扩展到新兴市场代表着巨大的成长机会。针对疫苗接种覆盖率低和疾病负担高的地区可以透过降低流感发病率来推动市场成长并改善全球健康。
• 开发下一代疫苗：投资开发下一代流感疫苗开启了成长机会，包括具有更广泛病毒株覆盖范围和更高功效的疫苗。这些疫苗可以解决当前的限制并满足不断变化的公共卫生需求，从而促进市场创新和扩张。
• 与公共卫生计划的整合：将流感疫苗整合到现有的公共卫生计划中，例如常规免疫接种和季节性健康宣传活动，提供了成长机会。将疫苗纳入综合健康策略可以提高疫苗接种覆盖率并更好地预防和控制疾病。
• 数位健康和​​疫苗追踪的进步：利用数位健康解决方案来追踪和管理疫苗带来了成长机会。行动应用程式和电子健康记录等数位工具可以增强疫苗接种流程、提高依从率并简化公共卫生活动。
• 策略伙伴关係和协作：与政府、非政府组织和私部门的策略伙伴关係和协作可以加强疫苗的分发和取得。这些伙伴关係可以透过提高疫苗供应、降低成本和扩大服务不足人口的覆盖范围来促进市场成长。

流感疫苗市场的策略性成长机会包括扩展到新兴市场、开拓下一代疫苗、与公共卫生计划的整合、数位健康的进步以及战略伙伴关係。这些机会将推动市场扩张、改善疫苗的取得并改善整体公共卫生结果。

流感疫苗市场推广因素及挑战

流感疫苗市场受到多种市场驱动因素和挑战的影响，包括技术进步、经济因素和监管问题。了解这些因素对于驾驭市场和推动成长至关重要。

推动流感疫苗市场的因素包括：

1.疫苗开发的技术进步：疫苗开发的技术进步：疫苗开发的技术进步，例如新配方和改进的递送方法，将推动市场开拓。这些创新将透过提高疫苗功效和应对大流行性流感来改善整体公共卫生结果。

2. 公众意识提升和健康宣传活动：关于流感疫苗接种重要性的公众意识提升和健康宣传活动将促进疫苗的接种。教育措施和有针对性的宣传活动有助于提高疫苗接种覆盖率并改善季节性流感的预防。

3. 政府资金和补贴：政府资金和补贴支持流感疫苗接种计划，使疫苗更容易获得。财政支持将有助于降低疫苗成本并鼓励更广泛的接种，特别是在服务不足和高风险族群中。

4. 流感及相关併发症发生率上升：流感及相关併发症的增加增加了对有效疫苗的需求。流感流行和重症病例数的增加凸显了改善疫苗接种策略的必要性，从而促进了市场成长。

5. 全球卫生伙伴关係和合作：全球卫生伙伴关係和合作将加强疫苗的分发和取得。政府、非政府组织和私人组织之间的合作将改善疫苗的供应并加速全球流感预防工作。

流感疫苗市场面临的挑战包括：

1. 疫苗犹豫和错误讯息：疫苗犹豫和错误讯息是提高疫苗接种率的挑战。解决公众的担忧并提供准确的资讯对于提高疫苗接种率和疫苗接种计划的成功至关重要。

2.疫苗成本高：疫苗成本上升会限制疫苗接种，特别是在低收入地区。解决负担能力问题对于提高疫苗供应和扩大覆盖范围至关重要。

3. 监管和合规挑战：复杂的监管和合规挑战难以克服。确保遵守不同的地区法规增加了疫苗开发和市场准入的复杂性。

流感疫苗市场的主要驱动因素包括技术进步、社会意识的提高、政府的财政支持、流感发病率的上升以及全球卫生伙伴关係。主要挑战包括疫苗接种犹豫、高成本和监管复杂性。解决这些市场驱动因素和挑战对于市场成长和改善公共卫生至关重要。

流感疫苗按市场

本研究按疫苗类型、分销管道和地区对全球流感疫苗进行了预测。

各国流感疫苗市场前景

流感疫苗市场的最新趋势集中在疫苗技术进步、监管变化和全球疫苗接种策略。这些发展正在塑造美国、中国、德国、印度和日本等关键地区的市场格局。

• 美国：在美国，自从四价疫苗推出以来，流感疫苗市场取得了进展。正在采用具有更高功效的改进配方，并将重点放在年度疫苗宣传活动上。 FDA 也核准了针对不同年龄层和高风险族群的可改善免疫反应的新疫苗。
• 中国：中国正致力于使用新的国产疫苗配方扩大流感疫苗接种计画。政府正在加强财政支持和补贴力度，帮助提高疫苗接种率。最近的进展包括新流感疫苗的核准以及提高农村和服务不足地区的疫苗接种覆盖率以有效缓解季节性流感爆发的努力。
• 德国：德国将更有效的新疫苗纳入国家免疫计划，在流感疫苗市场取得突破。为老年人引入高剂量和辅助疫苗反映了提高疫苗功效的努力。此外，公共卫生宣传活动正在加强，以鼓励增加不同族群的疫苗接种覆盖率。
• 印度：在印度，重点是提高疫苗的可用性和可负担性。新措施包括推出具有成本效益的流感疫苗和扩大农村地区的疫苗接种计划。政府和製药公司之间的伙伴关係旨在改善疫苗分配和疫苗接种覆盖率，并解决该国季节性流感的沉重负担。
• 日本：日本透过更新疫苗接种指南和改进疫苗配方开发了流感疫苗市场。值得注意的是，针对多种病毒株的疫苗的推出以及针对成人和儿童的疫苗宣传活动的扩大。日本也正在投资研究，以开发更有效的疫苗并改善公共卫生对流感的反应。

常问问题

Q.1 流感疫苗的市场规模有多大？

A1. 到2030年，全球流感疫苗市场预计将达到112亿美元。

Q.2 流感疫苗市场的成长预测如何？

A2. 2024年至2030年，全球流感疫苗市场预计将以6.8%的复合年增长率成长。

Q.3 影响流感疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动力是对更有效、侵入性更小的流感疫苗的需求不断增长、人们对流感疫苗益处的认识不断提高以及政府促进流感疫苗接种的支持措施。

Q4.市场的主要细分市场是：

A4. 流感疫苗市场前景看好，医院/零售药局和政府供应管道都有机会。

Q5.市场的主要企业是：

A5. 主要流感疫苗公司如下：

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Q6.未来最大的细分市场是什么？

A6. 由于灭活疫苗的安全性和有效性，其需求正在增加，我们预计在预测期内将出现高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于流感高发生率、完善的医疗保健系统以及对疫苗接种的偏好，预计北美在预测期内将出现最高的增长。

Q8. 可以客製化报告吗？

A8. 是的，我们提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球流感疫苗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球流感疫苗市场趋势（2018-2023）与预测（2024-2030）
• 全球流感疫苗市场：依疫苗类型
  • 惰性
  • 减毒活
• 全球流感疫苗市场：依分销管道划分
  • 医院/药房
  • 政府供应
  • 其他的

第四章市场趋势与预测分析：按地区划分，2018-2030

• 全球流感疫苗市场：按地区
• 北美流感疫苗市场
• 欧洲流感疫苗市场
• 亚太地区流感疫苗市场
• 其他地区流感疫苗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 按疫苗类型
  • 按分销管道
  • 按地区
• 全球流感疫苗市场新趋势
• 战略分析
  • 新产品开发
  • 全球流感疫苗市场产能扩张
  • 全球流感疫苗市场的合併、收购与合资
  • 认证和许可

第七章主要企业概况

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Influenza Vaccine Trends and Forecast

The future of the global influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030 with a CAGR of 6.8% from 2024 to 2030. The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

• Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.
• Within this market, hospital & retail pharmacy is expected to witness highest growth over the forecast period as they are the easiest and most accessible locations to acquire a flu vaccine.
• North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Emerging Trends in the Influenza Vaccine Market

Emerging trends in the influenza vaccine market reflect innovations in vaccine technology, expanded access, and evolving public health strategies. These trends are shaping the future of influenza prevention and treatment globally.

• Development of Quadrivalent and High-Dose Vaccines: The trend towards quadrivalent and high-dose vaccines is prominent. Quadrivalent vaccines cover four strains of the influenza virus, offering broader protection. High-dose vaccines are designed for older adults to improve immune response. These developments aim to enhance efficacy and provide better protection against influenza.
• Focus on Vaccine Innovation and Personalized Vaccines: Innovation in vaccine technology, including personalized vaccines tailored to individual genetic profiles, is gaining momentum. These advances promise more effective and targeted influenza prevention, potentially increasing vaccine uptake and improving overall public health outcomes.
• Increased Emphasis on Annual Vaccination: There is a growing emphasis on annual influenza vaccination to address seasonal variations in flu strains. Annual vaccination campaigns are becoming more widespread, aiming to boost vaccine coverage and reduce the incidence of influenza outbreaks each year.
• Expansion of Vaccination Programs to Underserved Areas: Expanding vaccination programs to underserved and rural areas is a key trend. Initiatives to increase vaccine accessibility in low-income and remote regions are being implemented to ensure broader coverage and reduce the disparity in influenza prevention.
• Integration with Digital Health Solutions: Integration of digital health solutions, such as electronic health records and mobile health apps, is improving vaccine tracking and management. Digital tools help streamline vaccination processes, enhance public health communication, and increase vaccine adherence rates.

Emerging trends such as the development of quadrivalent and high-dose vaccines, focus on vaccine innovation, increased emphasis on annual vaccination, expansion to underserved areas, and integration with digital health solutions are reshaping the influenza vaccine market. These trends enhance vaccine effectiveness, accessibility, and overall public health strategies.

Recent Developments in the Influenza Vaccine Market

Recent developments in the influenza vaccine market are marked by technological advancements, regulatory updates, and improved public health strategies. These developments are driving changes in vaccine effectiveness and accessibility.

• Introduction of Quadrivalent Vaccines: The introduction of quadrivalent vaccines, which cover an additional strain compared to trivalent vaccines, represents a significant development. These vaccines offer broader protection and are becoming the standard for influenza prevention, improving overall efficacy and reducing seasonal flu incidence.
• Advancements in High-Dose and Adjuvanted Vaccines: High-dose and adjuvanted vaccines have been developed to enhance immune response, especially in older adults. These vaccines are designed to address age-related declines in immunity, providing better protection and reducing the risk of severe influenza-related complications.
• Expansion of Vaccine Access Programs: Efforts to expand vaccine access through government subsidies and public health programs have increased. These programs aim to make vaccines more affordable and accessible, particularly in underserved populations and rural areas, thereby improving vaccination rates and public health outcomes.
• Emergence of New Vaccine Formulations: New vaccine formulations, including those with improved protection against multiple strains, have been introduced. These formulations enhance the ability to address evolving influenza viruses and improve vaccine effectiveness, contributing to better seasonal flu management.
• Global Collaboration for Vaccine Distribution: Global collaboration among governments, pharmaceutical companies, and health organizations has improved vaccine distribution. These partnerships help ensure that vaccines reach diverse populations, including those in low- and middle-income countries, enhancing global influenza prevention efforts.

Recent developments such as the introduction of quadrivalent vaccines, advancements in high-dose and adjuvanted vaccines, expansion of access programs, emergence of new formulations, and global collaboration are significantly impacting the influenza vaccine market. These advancements enhance vaccine effectiveness, accessibility, and overall public health outcomes.

Strategic Growth Opportunities for Influenza Vaccine Market

Strategic growth opportunities in the influenza vaccine market are driven by advancements in vaccine technology, increased global vaccination efforts, and evolving public health needs. These opportunities present potential for market expansion and improved health outcomes.

• Expansion into Emerging Markets: Expanding influenza vaccination programs into emerging markets offers significant growth opportunities. Targeting regions with low vaccination coverage and high disease burden can drive market growth and improve global health by reducing the incidence of influenza.
• Development of Next-Generation Vaccines: Investing in the development of next-generation influenza vaccines, such as those with broader strain coverage and improved efficacy, presents growth potential. These vaccines can address current limitations and meet evolving public health needs, driving market innovation and expansion.
• Integration with Public Health Programs: Integrating influenza vaccines with existing public health programs, such as routine immunizations and seasonal health campaigns, offers growth opportunities. By incorporating vaccines into comprehensive health strategies, vaccination rates can be increased, leading to better disease prevention and management.
• Advancements in Digital Health and Vaccine Tracking: Leveraging digital health solutions for vaccine tracking and management provides growth opportunities. Digital tools, including mobile apps and electronic health records, can enhance vaccination processes, improve adherence rates, and streamline public health efforts.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with governments, NGOs, and private sector players can enhance vaccine distribution and access. These partnerships can facilitate market growth by improving vaccine availability, reducing costs, and expanding coverage to underserved populations.

Strategic growth opportunities in the influenza vaccine market include expansion into emerging markets, development of next-generation vaccines, integration with public health programs, advancements in digital health, and strategic partnerships. These opportunities drive market expansion, improve vaccine accessibility, and enhance overall public health outcomes.

Influenza Vaccine Market Driver and Challenges

The influenza vaccine market is influenced by a range of drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these factors is crucial for navigating the market and fostering growth.

The factors responsible for driving the influenza vaccine market include:

1. Technological Advancements in Vaccine Development: Technological advancements in vaccine development, such as new formulations and improved delivery methods, drive market growth. These innovations enhance vaccine efficacy and address emerging influenza strains, improving overall public health outcomes.

2. Increased Public Awareness and Health Campaigns: Increased public awareness and health campaigns about the importance of influenza vaccination boost vaccine uptake. Educational initiatives and targeted campaigns contribute to higher vaccination rates and better prevention of seasonal flu.

3. Government Funding and Subsidies: Government funding and subsidies support influenza vaccination programs and make vaccines more accessible. Financial support helps reduce vaccine costs and promotes broader coverage, particularly in underserved and high-risk populations.

4. Rising Incidence of Influenza and Related Complications: The rising incidence of influenza and related complications drives demand for effective vaccines. Increased flu outbreaks and severe cases highlight the need for improved vaccination strategies and contribute to market growth.

5. Global Health Partnerships and Collaborations: Global health partnerships and collaborations enhance vaccine distribution and access. Collaborative efforts between governments, NGOs, and private organizations improve vaccine availability and facilitate global influenza prevention initiatives.

Challenges in the influenza vaccine market are:

1. Vaccine Hesitancy and Misinformation: Vaccine hesitancy and misinformation pose challenges to increasing vaccination rates. Addressing public concerns and providing accurate information are essential for improving vaccine uptake and ensuring the success of vaccination programs.

2. High Vaccine Costs: High vaccine costs can limit access, particularly in low-income regions. Addressing affordability issues is crucial for improving vaccine accessibility and achieving broader coverage.

3. Regulatory and Compliance Challenges: Navigating complex regulatory and compliance requirements can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

Major drivers of the influenza vaccine market include technological advancements, increased public awareness, government funding, rising influenza incidence, and global health partnerships. Key challenges include vaccine hesitancy, high costs, and regulatory complexities. Addressing these drivers and challenges is essential for market growth and improving public health outcomes.

List of Influenza Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies influenza vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the influenza vaccine companies profiled in this report include-

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Influenza Vaccine by Segment

The study includes a forecast for the global influenza vaccine by vaccine type, distribution channel, and region.

Influenza Vaccine Market by Vaccine Type [Analysis by Value from 2018 to 2030]:

• Inactivated
• Live Attenuated

Influenza Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Influenza Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Influenza Vaccine Market

Recent developments in the influenza vaccine market highlight advancements in vaccine technology, regulatory changes, and global vaccination strategies. These developments are shaping the market landscape in key regions including the United States, China, Germany, India, and Japan.

• United States: In the U.S. the influenza vaccine market has seen advancements with the introduction of quadrivalent vaccines, covering additional strains for broader protection. Enhanced formulations with higher efficacy rates are being adopted, and there is increased emphasis on annual vaccination campaigns. The FDA has also approved new vaccines with improved immune responses, targeting diverse age groups and high-risk populations.
• China: China has focused on expanding its influenza vaccination programs with new domestic vaccine formulations. The government has increased funding and subsidies to promote higher vaccine uptake. Recent developments include the approval of new influenza vaccines and efforts to improve vaccination coverage in rural and underserved areas, aiming to mitigate seasonal flu outbreaks effectively.
• Germany: Germany has made strides in the influenza vaccine market by incorporating newer, more effective vaccines into its national immunization program. The introduction of high-dose and adjuvanted vaccines for older adults reflects an effort to boost vaccine efficacy. Additionally, public health campaigns have been intensified to encourage higher vaccination rates across different demographics.
• India: In India, the focus has been on increasing vaccine accessibility and affordability. New initiatives include the launch of cost-effective influenza vaccines and expansion of vaccination programs in rural areas. Government partnerships with pharmaceutical companies aim to enhance distribution and coverage, addressing the high burden of seasonal influenza in the country.
• Japan: Japan has advanced its influenza vaccine market by updating vaccination guidelines and improving vaccine formulations. The introduction of vaccines with enhanced protection against multiple strains and extended vaccination campaigns for both adults and children are notable. Japan is also investing in research to develop more effective vaccines and improve public health responses to influenza.

Features of the Global Influenza Vaccine Market

Market Size Estimates: Influenza vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Influenza vaccine market size by vaccine type, distribution channel, and region in terms of value ($B).

Regional Analysis: Influenza vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different vaccine types, distribution channels, and regions for the influenza vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the influenza vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the influenza vaccine market size?

Answer: The global influenza vaccine market is expected to reach an estimated $11.2 billion by 2030.

Q.2 What is the growth forecast for influenza vaccine market?

Answer: The global influenza vaccine market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the influenza vaccine market?

Answer: The major drivers for this market are rising demand for more effective and less invasive influenza vaccines, growing awareness of the benefits of influenza vaccines, and supportive government initiatives to promote influenza vaccination.

Q4. What are the major segments for influenza vaccine market?

Answer: The future of the influenza vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key influenza vaccine market companies?

Answer: Some of the key influenza vaccine companies are as follows:

• GSK
• AstraZeneca
• SINOVAC
• Pfizer
• Vaxess Technologies
• CSL
• EMERGENT

Q6. Which influenza vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that inactivated is expected to witness higher growth over the forecast period due to growing demand for these vaccinations given to its safety and effectiveness.

Q7. In influenza vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to high prevalence of influenza, availability of well-established healthcare system, and high preference for vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the influenza vaccine market by vaccine type (inactivated and live attenuated), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Influenza Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Influenza Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Influenza Vaccine Market by Vaccine Type
  • 3.3.1: Inactivated
  • 3.3.2: Live Attenuated
• 3.4: Global Influenza Vaccine Market by Distribution Channel
  • 3.4.1: Hospital & Retail Pharmacies
  • 3.4.2: Government Suppliers
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Influenza Vaccine Market by Region
• 4.2: North American Influenza Vaccine Market
  • 4.2.1: North American Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated 4.2.2: North American Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.3: European Influenza Vaccine Market
  • 4.3.1: European Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.3.2: European Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.4: APAC Influenza Vaccine Market
  • 4.4.1: APAC Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.4.2: APAC Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
• 4.5: ROW Influenza Vaccine Market
  • 4.5.1: ROW Influenza Vaccine Market by Vaccine Type: Inactivated and Live Attenuated
  • 4.5.2: ROW Influenza Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Influenza Vaccine Market by Vaccine Type
  • 6.1.2: Growth Opportunities for the Global Influenza Vaccine Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Influenza Vaccine Market by Region
• 6.2: Emerging Trends in the Global Influenza Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Influenza Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Influenza Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GSK
• 7.2: AstraZeneca
• 7.3: SINOVAC
• 7.4: Pfizer
• 7.5: Vaxess Technologies
• 7.6: CSL
• 7.7: EMERGENT